![](/img/cover-not-exists.png)
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
Kim, Dennis Dong Hwan, Hamad, Nada, Lee, Hong Gi, Kamel-Reid, Suzanne, Lipton, Jeffrey H.Volume:
89
Language:
english
Journal:
American Journal of Hematology
DOI:
10.1002/ajh.23707
Date:
June, 2014
File:
PDF, 747 KB
english, 2014